NCT06138327View on ClinicalTrials.gov

A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 26, 2023

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions
HyperoxaluriaNonalcoholic Fatty Liver DiseaseKidney Stone
Interventions
DRUG

BMN 255

Oral Capsule

DRUG

Placebo

Oral Capsule

Trial Locations (7)

30044

Georgia Clinical Research, LLC, Lawrenceville

35249

University of Alabama - Department of Urology, Birmingham

43213

Centricity Research, Columbus

45227

Medpace Clinical Pharmacology Unit, Cincinnati

77054

Prolato Clinical Research Center, Houston

91911

ProSciento, Inc., Chula Vista

ProSciento, Inc., Chula Vista Isles

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY